AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26022709
Drug: FLAM (flavopiridol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLAM (flavopiridol 50 mg/m(2) days 1‐3, cytarabine 667 mg/m(2)/day continuous infusion days 6‐8, and mitoxantrone 40 mg/m(2) day 9)
Trial: 26022709
Drug: 7+3 (cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7+3 (cytarabine 100 mg/m(2)/day continuous infusion days 1‐7 and daunorubicin 90 mg/m(2) days 1‐3)
Trial: 26022709
Drug: 7+3+/-5+2 (cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7+3+/-5+2 (cytarabine 100 mg/m(2)/day continuous infusion days 1‐5 and daunorubicin 45 mg/m(2) days 1‐2)
Trial: 21497022
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg followed by two boluses of 0.5 mg/kg at 5-min intervals and continuous infusion)
Trial: 21497022
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sodium chloride administered at equivalent volume, dose and rate to lidocaine)
Trial: 12925034
Drug: Lepirudin (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lepirudin (bolus 0.1 mg kg‐1, continuous infusion of 0.1 mg kg‐1 h‐1)
Trial: 12162483
Drug: HPMC-containing solution
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC-containing solution
Trial: 12162483
Drug: Multipurpose solutions
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multipurpose solutions without HPMC
Trial: 9672932
Drug: Withholding oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding oral fluids for 4-6 hours postoperatively
Trial: 9672932
Drug: Drinking oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking oral fluids postoperatively
Trial: 9672932
Drug: Withholding oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding oral fluids in patients receiving opioids
Trial: 7916445
Drug: Atropine and
RxNorm normalized name: atropine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine and chlordesmethyldiazepam (0.03 mg/kg)
Trial: 7916445
Drug: Atropine and
RxNorm normalized name: atropine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine and diazepam (0.015 mg/kg)
Trial: 2690395
Drug: 252Cf neutron
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 252Cf neutron component applied by means of intracavitary therapy at the beginning of the therapeutic cure
Trial: 2690395
Drug: Conventional 226Ra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 226Ra therapy (control group)
Trial: 21192304
Drug: Clonidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (200 or 400 mcg)
Trial: 21192304
Drug: Triamcinolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (40 mg)
Trial: 19523011
Drug: 180 microg
RxNorm normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 microg week(‐1) PEG‐IFN alpha‐2a (40KD) + ribavirin (1000/1200 mg day(‐1)) for 48 weeks
Trial: 19523011
Drug: 270 microg
RxNorm normalized name: Interferon alfa-2a (as peginterferon alfa-2a) 270 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 microg week(‐1) PEG‐IFN alpha‐2a (40KD) + ribavirin (1000/1200 mg day(‐1)) for 48 weeks
Trial: 17577435
Drug: Specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific treatment group (intravascular embolism followed by immediate CSF drainage)
Trial: 17577435
Drug: Conventional expectant
RxNorm normalized name: docosahexaenoic acid Oral Capsule [Expecta]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional expectant treatment group
Trial: 11432512
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with 0.2% glyceryl trinitrate ointment
Trial: 20037779
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (FEC-P)
Trial: 11030486
Drug: Mirtazapine (15‐45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15‐45 mg/day)
Trial: 29734896
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg triamcinolone acetonide
Trial: 29734896
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg triamcinolone acetonide
Trial: 24597289
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of GnRH agonist with recombinant hCG (rhCG)
Trial: 20431040
Drug: Cyclosporine monotherapy
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine monotherapy followed by azathioprine and prednisolone after 3 months
Trial: 18378552
Drug: Mecamylamine (MECA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine (MECA, 20 mg, oral)
Trial: 10359889
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol xinafoate 42 microgram twice daily
Trial: 11549982
Drug: Oral zafirlukast
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral zafirlukast 20 mg twice daily
Trial: 1749203
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg b.i.d.)
Trial: 1709240
Drug: Chlorthalidone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (25 mg o.d.)
Trial: 1709240
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nifedipine and chlorthalidone (20 mg b.i.d. and 25 mg o.d.)
Trial: 31178377
Drug: ROTAVAC® (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROTAVAC® (3 doses)
Trial: 31178377
Drug: Rotarix® (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotarix® (2 doses)
Trial: 23106838
Drug: Fissure sealant
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fissure sealant with oral hygiene instructions
Trial: 17764475
Drug: 30 min
RxNorm normalized name: Goddess Garden SPF 30 Mineral Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 min exercise starting immediately after dosing (EX0)
Trial: 17620446
Drug: 30 min
RxNorm normalized name: Goddess Garden SPF 30 Mineral Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 min exercise starting 30 min after dosing (EX30)
Trial: 16123473
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (RHI)
Trial: 12691686
Drug: Weekly provider-initiated
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly provider-initiated follow-up calls for 1 month post-education
Trial: 3797487
Drug: Salt tablets
RxNorm normalized name: bile salts Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt tablets for 4 weeks
Trial: 3797487
Drug: Salt tablets
RxNorm normalized name: bile salts Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt tablets for 6 weeks
Trial: 21989635
Drug: Repetitive task
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repetitive task specific training (RTP) for 6 weeks, approximately 2.5 hours per day, split into two sessions, with epidural cortical stimulation co-administered
Trial: 22835600
Drug: Omega-3 polyunsaturated
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 polyunsaturated fatty acids (PUFAs) administered at ≥2.7 g/day for a minimum duration of 3 months
Trial: 17607078
Drug: Nutritional agents
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional agents such as active vitamin D3 and vitamin K2
Trial: 12006898
Drug: Moclobemide (75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (75, 150, 300, 600, or 900 mg/day)
Trial: 10096263
Drug: Interleukin-10 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-10 (8 microg/kg subcutaneous injection)
Trial: 10096263
Drug: Prednisolone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (15 mg by mouth)
Trial: 8641320
Drug: Idrapril calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idrapril calcium (200 mg)
Trial: 6928104
Drug: Induction regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction regimen (vincristine plus low-dose methotrexate and high-dose prednisone)
Trial: 27967288
Drug: Kabat physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kabat physical rehabilitation combined with steroid treatment
Trial: 27967288
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment alone
Trial: 26055847
Drug: Oral iron,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron, folic acid, and anthelminthics prescribed after the first ANC visit.
Trial: 24634110
Drug: Lacosamide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (200 mg twice daily)
Trial: 15331966
Drug: Temporal lobectomy
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporal lobectomy for drug-resistant temporo-mesial epilepsy
Trial: 2651493
Drug: Zolpidem 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 5.0 mg and larger doses
Trial: 2651493
Drug: Zolpidem 7.5
RxNorm normalized name: zolpidem 7.5 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 7.5 mg and higher doses
Trial: 28573779
Drug: Daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of skincare (Normaderm®) with fixed combination of adapalene/benzoyl peroxide
Trial: 28573779
Drug: Standard emollient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard emollient alone with fixed combination of adapalene/benzoyl peroxide
Trial: 23356386
Drug: MBL-HCV1 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBL-HCV1 (50 mg/kg, 11 infusions)
Trial: 19746439
Drug: Leukotriene receptor
RxNorm normalized name: Leukotriene receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene receptor antagonists (LTRAs) in addition to fexofenadine (FEX) for 16 weeks
Trial: 15345796
Drug: t‐PA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA therapy
Trial: 11774075
Drug: Intravenous ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ribavirin treatment
Trial: 9015579
Drug: Yohimbine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (up to 30 mg/day)
Trial: 8235862
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation over the lower lumbar paraspinal muscles for 30 minutes twice a day.
Trial: 28643069
Drug: Laparoscopic HIPEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic HIPEC with Mitomycin C 30 mg and Cisplatin 200 mg in 3-7 L of infusate for 60 min, performed up to five times.
Trial: 19942485
Drug: ALV003 pre-treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALV003 pre-treated gluten (16 g daily for 3 days)
Trial: 19942485
Drug: Placebo pre-treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pre-treated gluten (16 g daily for 3 days)
Trial: 17511533
Drug: Cognitive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive treatment group (n=16)
Trial: 17511533
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment group (n=26)
Trial: 11953285
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (Group B)
Trial: 10364647
Drug: Tacrine 30
RxNorm normalized name: tacrine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine 30 mg/day for 6 weeks, 60 mg/day for 6 weeks, 90 mg/day for 6 weeks, 120 mg/day for 12 weeks
Trial: 31265113
Drug: Dietary lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lysine level of 6.4 g/kg
Trial: 31265113
Drug: Dietary lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lysine level of 7.2 g/kg
Trial: 31265113
Drug: Dietary lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lysine level of 8.0 g/kg
Trial: 31265113
Drug: Dietary lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lysine level of 8.8 g/kg
Trial: 31265113
Drug: Dietary lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lysine level of 9.6 g/kg
Trial: 31265113
Drug: Dietary lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lysine level of 10.4 g/kg
Trial: 31265113
Drug: Dietary lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lysine level of 8.6 g/kg
Trial: 27400922
Drug: Case Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case Management (CM) intervention consisting of assistance in obtaining income entitlements, referral to primary or specialty medical care, access to mental health care or substance abuse treatment, and counseling on at-risk behaviors and health care utilization.
Trial: 24326412
Drug: Internal medicine/endocrinology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal medicine/endocrinology practice
Trial: 15831772
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (inhaled corticosteroids, 2 mg)
Trial: 15831772
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (oral corticosteroids, 50 mg)
Trial: 11691516
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen, 0.625 mg/day for 8 weeks
Trial: 3280614
Drug: Dilazep (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilazep (0.2 mg/kg body weight by IV infusion for ten minutes)
Trial: 31720819
Drug: Aspirin or
RxNorm normalized name: aspirin Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin or cilostazol treatment with best medical therapy
Trial: 29318443
Drug: Push intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Push intervention components of mHealth interventions (e.g., notifications or text messages)
Trial: 29165753
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 0.5 μg/kg remifentanil (Control group)
Trial: 29165753
Drug: Atomization inhalation
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomization inhalation of 15 mg ambroxol hydrochloride and 0.5 mg budesonide suspension (Observation group)
Trial: 25831405
Drug: H2N2 live
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2N2 live attenuated influenza vaccine (LAIV)
Trial: 22633044
Drug: Cerebral protection
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral protection device (CPD) used in treatment
Trial: 16430773
Drug: Starting calcium
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting calcium supplements
Trial: 15928285
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug treatment
Trial: 1466432
Drug: Fentanyl/propofol anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl/propofol anaesthesia (propofol infusion 6 mg.kg‐1.h‐1, reduced after 10 min)
Trial: 6230648
Drug: Mezlocillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin (2 g dose administered intravenously 1 hour before surgery)
Trial: 30693399
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement + deproteinized bovine bone derived with collagen
Trial: 30693399
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement without biomaterial
Trial: 26500463
Drug: Zeolite supplementation
RxNorm normalized name: zeolite A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zeolite supplementation (1.85 g per day for 12 weeks)
Trial: 21552183
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg mpHBV
Trial: 21552183
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg mpHBV
Trial: 21552183
Drug: Recombivax‐HB (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombivax‐HB (5 μg)
Trial: 21552183
Drug: Engerix‐B (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix‐B (10 μg)
Trial: 19843809
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg oral ondansetron the evening before surgery plus IV 8 mg ondansetron 15 min before subarachnoid anesthesia
Trial: 10088569
Drug: rhGH, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH, 0.2 mg/kg per day intramuscularly (n = 10)
Trial: 7502702
Drug: Calcium (1
RxNorm normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1 g of calcium)
Trial: 1953991
Drug: Alcohol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.75 g/kg body weight in 500 ml carbon dioxide‐free mineral water)
Trial: 1953991
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (1,000 mg powdered, average 13.1 mg/kg body weight)
Trial: 1953991
Drug: Alcohol and
RxNorm normalized name: Polyvinyl alcohol and povidone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol and acetylsalicylic acid combination
Trial: 24755382
Drug: Cronus (stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cronus (stent without polymer coating or drug elution)
Trial: 22762317
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (≥800 IU daily)
Trial: 22762317
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (unspecified dosage)
Trial: 18784223
Drug: Praziquantel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (40 mg/kg) at baseline
Trial: 15916656
Drug: Dinoprostone gel
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone gel (0.5 mg intracervically)
Trial: 15916656
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (GTN) (0.5 mg perivaginally)
Trial: 15916656
Drug: Dinoprostone gel
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone gel (0.5 mg intracervically) in severely unfavorable cervix (Bishop score ≤3)
Trial: 15916656
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (GTN) (0.5 mg perivaginally) in severely unfavorable cervix (Bishop score ≤3)
Trial: 3525337
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg at night
Trial: 12643609
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg in the morning
Trial: 6778754
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (15 mg)
Trial: 22113218
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (40 mg triamcinolone acetonide)
Trial: 15708886
Drug: lamivudine 150
RxNorm normalized name: lamivudine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamivudine 150 mg twice daily
Trial: 12468950
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.), amoxycillin (1 g b.d.) for 7 days
Trial: 12468950
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.) for 5 days
Trial: 12468950
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.) for 7 days
Trial: 12468950
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.) for 10 days